Help | Scores |Exit
Fragmin | Magnex | Solu Medrol
Perindopril Drug Name:  
A|B|C|D|E|F|G|H|I|K|L|M|N|O|P|Q|R|S|T|V|Z
Indications
Dosages
Interactions
Precautions
Contraindications
Adverse Reactions
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interactions:

Allopurinol

  • Adverse Effect: hypersensitivity reactions (Stevens-Johnson syndrome, skin eruptions)  
  • Clinical Management: If these drugs are used concurrently, monitor for hypersensitivity reactions.

    Amiloride

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Aspirin

  • Adverse Effect: decreased captopril effectiveness  
  • Clinical Management: Although studies have suggested an interaction between Perindopril and aspirin, the clinician should weigh the benefits against the risks of combining these two agents.

    Bumetanide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Celecoxib

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Chlorthalidone

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Perindopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Clopamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of Perindopril in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Diclofenac Preps.

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Erythropoietin

  • Adverse Effect: higher maintenance doses of erythropoietin to maintain the target hematocrit  
  • Clinical Management: Monitor patients receiving angiotensin converting enzyme inhibitors for erythropoietin efficacy. When given concomitantly, doses of erythropoietin may be higher than expected.

    Flurbiprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Frusemide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Ibuprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Indapamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.

    Indomethacin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketoprofen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Ketorolac

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Lithium

  • Adverse Effect: Lithium toxicity (weakness, tremor, excessive thirst, confusion) and/or nephrotoxicity  
  • Clinical Management: The combination of lithium and Perindopril should be avoided if possible, though the choice of an alternative antihypertensive agent that does not interact with lithium is limited. If lithium and Perindopril are used concurrently, serum lithium levels should be closely monitored and the patient followed for any symptoms of lithium toxicity.

    Mefenamic Acid

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Meloxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nabumetone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Naproxen

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Nimesulide

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Oxyphenbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Paracetamol

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenacetin

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Phenylbutazone

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Piroxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Spironolactone

  • Adverse Effect: hyperkalemia  
  • Clinical Management: Although such increases are usually transient, monitor serum potassium levels for persistent elevations in patients on this combination, especially in patients with renal dysfunction or diabetes and the elderly. Severe arrhythmias and death have been reported from hyperkalemia with such combinations.

    Tenoxicam

  • Adverse Effect: Decreased antihypertensive and natriuretic effects  
  • Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.

    Xipamide

  • Adverse Effect: postural hypotension (first dose)  
  • Clinical Management: Start with a very low dose of the angiotensin converting enzyme (ACE) inhibitor in the evening and closely monitor blood pressure for a severe hypotensive response for four hours after the initial dose. Monitor for hypotension, fluid status, and body weight regularly for up to two weeks after dose adjustments.
  • Penicillamine
    Penicillin G Benzathine
    Penicillin G Potassium
    Penicillin G Procaine
    Penicillin V Potassium
    Pentamidine Isethionate
    Phenobarbital
    Phenylephrine Hydrochloride
    Phenytion
    Physostigmine Salicylate
    Pilocarpine Hydrochloride
    Piperacillin Sodium
    Polysaccharide Iron Complex
    Potassium Iodide
    Potassium Salts
    Prazosin Hydrochloride
    Prednisolone
    Prednisolone Acetate
    Prednisone
    Primaquine Phosphate
    Primidone
    Probenecid
    Procainamide Hydrochloride
    Promethazine Hydrochloride
    Propranolol Hydrochloride
    Propylthiouracil
    Protamine Sulfate
    Pseudoephedrine Hydrochloride
    Pyrantel Pamoate
    Pyridoxine Hydrochloride
    Paclitaxel
    Pamidronate
    Pancuronium
    Pantoprazole
    Paracetamol
    Pas
    Pefloxacin
    Pefloxacin - Ocular
    Penfluridol
    Penicillin V Phenoxymethyl
    Pentaerythritol Tetranitrate
    Pentazocine
    Pentoxyfylline
    Perindopril
    Permethrin
    Pethidine
    Phenacetin
    Phenazopyridine
    Phenformin
    Phenindione
    Pheniramine Maleate
    Phenobarbitone
    Phenophthalein
    Phenoxybenzamine
    Phenylbutazone
    Phenylephrine
    Phytoestrogens
    Pilocarpine
    Pimozide
    Pindolol
    Pioglitazone
    Pipecuronium
    Pipenzolate Methyl Br - Antispas
    Piperacillin
    Piperazine
    Piracetam
    Piribedil
    Piroxicam
    Pneumococcal vaccine
    Polidocanol
    Polymyxin B - Ocular
    Polymyxin-B
    Potassium citrate + citric acid
    Povidone Iodine
    Povidone Iodine - VU
    Pralidoxime
    Pravastatin sodium
    Praziquantel
    Prazosin
    Prazosin - BPH
    Prednisolone - Topical
    Prednisolone - resp
    Primaquine
    Procainamide
    Procaine Penicillin
    Prochlorperazine
    Procyclidine
    Progesterone
    Proguanil
    Promethazine
    Propantheline Br
    Propantheline Br - Antispas
    Propofol
    Propranolol
    Psoralen
    Pyrazinamide
    Pyridostigmine
    Pyrimethamine
    Pyritinol
     
    Disclaimer